Clinical Trials Logo

Advanced Solid Tumors clinical trials

View clinical trials related to Advanced Solid Tumors.

Filter by:

NCT ID: NCT00908908 Completed - Clinical trials for Advanced Solid Tumors

A Study to Determine the Metabolism and Elimination of Carbon-14 Labeled Eribulin Acetate (14C-Eribulin) in Patients With Advanced Solid Tumors

Start date: March 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the metabolism and elimination of carbon-14 labeled eribulin acetate (14C-eribulin) in patients with advanced solid tumors.

NCT ID: NCT00891280 Recruiting - Breast Cancer Clinical Trials

Dose-escalation Study of Oral CX-4945

Start date: February 2009
Phase: Phase 1
Study type: Interventional

This Phase 1 study of oral CX-4945 is designed to test the safety, tolerability and highest safe dose level of this CK2 inhibitor in patients with advanced solid tumor cancers, Castleman's Disease or Multiple Myeloma.

NCT ID: NCT00881244 Completed - Clinical trials for Advanced Solid Tumors

Study of AS1411 in Advanced Solid Tumours

Start date: September 2003
Phase: Phase 1
Study type: Interventional

A Phase I open label study of AS1411 in advanced solid tumours. Objectives include determining the MTD and DLT of AS1411, to determine the PK profile of AS1411 and to obtain preliminary evidence of clinical and biological responses to AS1411 therapy.

NCT ID: NCT00879684 Completed - Cancer Clinical Trials

Safety And PK Study Of CVX-060 In Patients With Advanced Solid Tumors

Start date: January 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety and tolerability of CVX-060 in patients with advanced solid tumors.

NCT ID: NCT00879554 Completed - Cancer Clinical Trials

A Safety And Pharmacokinetic Study With CVX-045 In Patients With Advanced Solid Tumors

CVX-045-101
Start date: February 2007
Phase: Phase 1
Study type: Interventional

The purpose of the study is to determine safety and tolerability of CVX-045 in patients with advanced solid tumors.

NCT ID: NCT00877474 Completed - Clinical trials for ADVANCED SOLID TUMORS

Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors

Start date: March 2009
Phase: Phase 1
Study type: Interventional

This is a phase I, multicenter, open-label, dose escalating clinical and pharmacokinetic study of PM01183 for patients with advanced solid tumors

NCT ID: NCT00874042 Completed - Clinical trials for Advanced Solid Tumors

Dose Escalation Study of ARQ 197 in Combination With Gemcitabine in Adult Patients With Advanced Solid Tumors

Start date: March 2009
Phase: Phase 1
Study type: Interventional

This is an open-label, dose-escalation/de-escalation study of ARQ 197 administered orally in combination with gemcitabine. The study is designed to determine the safety, tolerability and maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of ARQ 197 when administered in combination with gemcitabine to patients with advanced solid tumors.

NCT ID: NCT00861419 Completed - Clinical trials for Advanced Solid Tumors

To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.

Start date: December 2005
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of AMG 386 when used in combination with AMG 706, bevacizumab, sorafenib, or sunitinib and that at least one dose level from each combination will be safe and well tolerated. AMG 386 is a man-made medication that is designed to stop the development of blood vessels in cancer tissues. Cancer tissues rely on the development of new blood vessels, a process called angiogenesis, to obtain a supply of oxygen and nutrients to grow.

NCT ID: NCT00861328 Completed - Clinical trials for Advanced Solid Tumors

Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin

Start date: February 2008
Phase: Phase 1
Study type: Interventional

Treatment of cancer is often improved if two or more drugs are used in combination. In animal studies, the use of the combination of ON 01910.Na (a new, unapproved drug) and irinotecan or oxaliplatin (two approved and extensively used anti-cancer drugs) gave better results against tumor cells than the use of any of the single drugs alone. In addition, the use of the combinations did not result in an increase of side effects. This clinical trial will determine what is the highest dose of ON 01910.Na that can be given safely in combination with either irinotecan or oxaliplatin in human patients.

NCT ID: NCT00858377 Completed - Cancer Clinical Trials

A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors

Start date: August 10, 2009
Phase: Phase 1
Study type: Interventional

This first-in-human study of AMG 900 will be conducted in two parts: dose escalation and dose expansion. The dose escalation part of the study is aimed at evaluating the safety, tolerability and PK of oral AMG 900 in subjects with advanced solid tumors. Up to 50 subjects may be enrolled in dose escalation. The dose expansion part of the study will consist of 42 subjects in three taxane-resistant tumor types. The dose of AMG 900 will be dependent upon data from the dose escalation part of the study